CEO did not lie in June,2011 in his comments to Bloomberg.The offers were closer to 15 than 30.
Read the statement carefully.
Now--in June,2011, Amarin had
1) No patents
2) Vascepa was not approved
3) Anchor 3 trial data for 200-500mg polulation was NOT available--This is a big opportunity.
4) Reduce-It study costing 120 mil.$ was not launched.
How can PFE or AZN or others offer price over 20 in May,2011?
Facts now are better--that is why 8 analysts--are estimating Value between 21.50 to 28$/share.
What is missing?
approval for 200-500mg.trigl.population--expected by Aug.2013
Sales for Vascepa
Based on Lipitor analogy from 1996-99,Vascepa is in 1996 stage.
1997-98 provided sales data,bidding followed in 1999.
Price offered -90 bil.$ in 1999 was 3 times what Pfizer was willing to offer in 1996.